2 excellent healthcare ASX shares with strong long term growth potential

Pro Medicus Limited (ASX:PME) and this ASX healthcare share could be outstanding buy and hold options for investors…

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Because of a number of favourable tailwinds including ageing populations, better technologies and treatments, and increased chronic disease burden, demand for healthcare services is expected to increase strongly over the next few decades.

As a result of this, the healthcare sector has been tipped as an area of the market to consider for long term investments.

But which healthcare ASX shares should you buy? Two that are highly rated are listed below:

Cochlear Limited (ASX: COH)

The first ASX healthcare share to look at is Cochlear. It is a global leader in the development, manufacture, and distribution of cochlear implantable devices for the hearing impaired.

After being hit hard by the pandemic, Cochlear bounced back incredibly strongly during the first half of FY 2021. In fact, for the six months ended 31 December, Cochlear recorded an underlying net profit of $125.3 million.

This was down just 4% in constant currency from its record first half profit a year earlier. It is worth remembering that the prior corresponding period was before COVID-19, which demonstrates just how quickly it has rebounded.

Positively, due to its strong market position and the industry's high barriers to entry, Cochlear looks well-placed for growth over the long term. Especially given how hearing loss is typically a part of getting older and the number of over 65s is expected explode over the coming decades.

Macquarie is positive on the company. Its analysts currently have an outperform rating and $245.00 price target on Cochlear's shares.

Pro Medicus Limited (ASX: PME)

Another ASX healthcare share to look at is Pro Medicus. It is a healthcare technology company that provides healthcare organisations with radiology information systems, picture archiving and communication systems, and advanced visualisation solutions.

Pro Medicus has been growing strongly over the last few years. This has been driven by its industry-leading technology and the structural shift away from legacy systems.

Positively, the company has continued this positive form in FY 2021. For example, in February the company reported a 7.8% increase in revenue to $31.6 million and a 25.9% jump in underlying profit before tax to $18.76 million.

The good news is that more of the same is expected in the second half. Particularly given how Pro Medicus has won a number of lucrative contracts with major healthcare institutions since the turn of the year.

Looking ahead, the company still has a large pipeline of sales opportunities that could be converted in the near future and drive further growth.

Goldman Sachs is a fan of Pro Medicus. The broker currently has a buy rating and $53.80 price target on its shares.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two doctors smile as they sit together at a desk looking at a patient's x-ray.
Healthcare Shares

Why Macquarie rates this ASX All Ords medical imaging stock a buy

The broker maintains its outperform rating on the stock.

Read more »

A man in a hospital bed on a drip gives a thumbs up sign.
Healthcare Shares

Macquarie predicts 86% upside for this ASX 200 healthcare stock

Shares could almost double over the next 12 months, according to the broker.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares?

Novo Nordisk just lost $100 billion in market value.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 11% today

Let's see why investors are bidding this stock higher on Wednesday.

Read more »

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »